ESR1 and cancer: Given that a substantial fraction of luminal B cancers are HER2‐positive (≈41%), our findings in the ERα‐responsive MMTV‐HER2/neu mice model support the plausibility of a DEHP‐facilitated early‐onset trajectory within both luminal A and B diseases.